Anti-Human Claudin-18.2 Recombinant Antibody (MIL93) (HX126033)

Name: Anti-Human Claudin-18.2 Recombinant Antibody (MIL93)
Brand: abinScience
SKU: HX126033
Price: 191 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

50ug
100ug
1mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.

HX126033

Description

Anti-Human Claudin-18.2 Recombinant Antibody (MIL93) (HX126033) is a human monoclonal antibody detecting Claudin-18.2 in ELISA, FCM, Functional assay. Suitable for Human.

Highlights

●Affinity Purified — Minimal background and high purity for reliable results.
●Multi-Application — Validated across multiple applications.

Species reactivity

Human

Applications

ELISA, FCM, Functional assay

Host species

Human

Clonality

Monoclonal

Isotype

IgG1, kappa

Clone ID

MIL93

Target

CLDN18.2, Claudin-18.2

Endotoxin level

< 10 EU/mg

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P56856-2

Form

Liquid

Storage buffer

0.01M PBS pH 7.4.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information

Application	Dilution
ELISA	1:2000-1:20000

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Background

Claudin-18 (CLDN18.2) is a ~27 kDa protein. Involved in alveolar fluid homeostasis via regulation of alveolar epithelial tight junction composition and therefore ion transport and solute permeability, potentially via downstream regulation of the actin cytoskeleton organization and beta-2-adrenergic signaling. Required for lung alveolarization and maintenance of the paracellular alveolar epithelial barrier. Acts to maintain epithelial progenitor cell proliferation and organ size, via regulation of YAP1 localization away from the nucleus and thereby restriction of YAP1 target gene transcription. Acts as a negative regulator of RANKL-induced osteoclast differentiation, potentially via relocation of TJP2/ZO-2 away from the nucleus, subsequently involved in bone resorption in response to calcium deficiency. Mediates the osteoprotective effects of estrogen, potentially via acting downstream of estrogen signaling independently of RANKL signaling pathways. CLDN18.2 is the therapeutic target of zolbetuximab (Vyloy).

Note

For research use only

Images

References

Datasheet